- Highlighted Item:
- Webinar:
- Publisher:Elsevier
- Publication Date:Apr 2012
- Reference:Regulatory Toxicology and Pharmacology, 2012, 62(3), pp449-455
- DOI:10.1016/j.yrtph.2012.01.007
- PMID:
- Publication Type:Paper
- Scientific Area:
- Endpoint:
- Industry Type:
In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: An industry survey
With the increasing emphasis on identification and low level control of potentially genotoxic impurities (GTIs), there has been increased use of structure-based assessments including application of computerized models. To date many publications have focused on the ability of computational models, either individually or in combination, to accurately predict the mutagenic effects of a chemical in the Ames assay. Typically, these investigations take large numbers of compounds and use in silico tools to predict their activity with no human interpretation being made. However, this does not reflect how these assessments are conducted in practice across the pharmaceutical industry. Current guidelines indicate that a structural assessment is sufficient to conclude that an impurity is non-mutagenic.
